drugset / Trial / NCT05137496
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone regimens as the first-line therapy .
Timeline
- Start
- 2022-06-01
- Primary completion
- 2023-06-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylprednisolone | Other / unclassified | 2 mg/kg | — |
| Subject | Ruxolitinib | Small molecule | 0.3 mg/kg | Intravenous |